Technical Analysis for MEIP - MEI Pharma, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Historical MEIP trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | -3.99% | |
| Bearish Engulfing | Bearish | -7.55% | |
| 20 DMA Support | Bullish | -7.55% | |
| 50 DMA Resistance | Bearish | -9.86% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -9.86% | |
| Crossed Above 20 DMA | Bullish | -8.59% | |
| MACD Bullish Signal Line Cross | Bullish | -8.59% | |
| Inside Day | Range Contraction | -4.28% | |
| Down 3 Days in a Row | Weakness | -2.26% | |
| 20 DMA Resistance | Bearish | -2.84% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Down 5% | 18 minutes ago |
| Down 3% | 44 minutes ago |
| Down 2 % | 44 minutes ago |
| Down 1% | about 1 hour ago |
| Fell Below Previous Day's Low | about 1 hour ago |
Get this analysis on your stocks daily!
- Earnings date: 05/01/2021
MEI Pharma, Inc. Description
MEI Pharma, Inc., a development stage oncology company, focuses on the clinical development of therapeutics for the treatment of cancer. It develops various lead drug candidates, including ME-143 that has completed Phase I clinical trials in patients with refractory solid tumors; ME-344, an active metabolite of NV-128, which is in Phase I clinical trials in patients with solid refractory tumors; and Pracinostat, an orally histone deacetylase inhibitor that has completed various Phase I clinical trials in patients with hematologic disorders. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California. MEI Pharma, Inc. is a subsidiary of Novogen Limited. MEI Pharma, Inc. (NasdaqCM:MEIP) operates independently of Novogen Limited as of December 03, 2012.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Cancer Clinical Medicine Clinical Development Solid Tumors Treatment Of Cancer Virotherapy Edwards Novogen Histone Deacetylase Inhibitor Refractory Solid Tumors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.575 |
| 52 Week Low | 2.28 |
| Average Volume | 981,934 |
| 200-Day Moving Average | 3.14 |
| 50-Day Moving Average | 3.70 |
| 20-Day Moving Average | 3.48 |
| 10-Day Moving Average | 3.47 |
| Average True Range | 0.23 |
| ADX | 12.04 |
| +DI | 19.69 |
| -DI | 19.43 |
| Chandelier Exit (Long, 3 ATRs ) | 3.15 |
| Chandelier Exit (Short, 3 ATRs ) | 3.87 |
| Upper Bollinger Band | 3.76 |
| Lower Bollinger Band | 3.20 |
| Percent B (%b) | 0.32 |
| BandWidth | 16.10 |
| MACD Line | -0.04 |
| MACD Signal Line | -0.05 |
| MACD Histogram | 0.0083 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.68 | ||||
| Resistance 3 (R3) | 3.70 | 3.62 | 3.63 | ||
| Resistance 2 (R2) | 3.62 | 3.54 | 3.61 | 3.61 | |
| Resistance 1 (R1) | 3.50 | 3.50 | 3.46 | 3.48 | 3.60 |
| Pivot Point | 3.42 | 3.42 | 3.40 | 3.41 | 3.42 |
| Support 1 (S1) | 3.30 | 3.34 | 3.26 | 3.28 | 3.16 |
| Support 2 (S2) | 3.22 | 3.30 | 3.21 | 3.15 | |
| Support 3 (S3) | 3.10 | 3.22 | 3.13 | ||
| Support 4 (S4) | 3.08 |
